Business Context and Reporting Period
This Form 6-K filing by Mereo Biopharma Group Plc (Mereo) covers the month of May 2019, specifically dated May 7, 2019. Mereo is a clinical-stage UK-based biopharmaceutical company focused on rare diseases. The company operates a pipeline of six product candidates, including four acquired prior to the OncoMed merger and two added through that merger (Navicixizumab and Etigilimab).
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures. The primary financial disclosure relates to a capital structure adjustment:
- Warrant Issuance: The Company issued warrants to lenders (Silicon Valley Bank and Kreos Capital V (UK) Limited) in connection with loan agreement revisions.
- Warrant Terms: Rights to subscribe for 321,444 shares at an exercise price of 295 pence per share.
- Dilution Impact: The warrants represent approximately 0.3% of the issued share capital.
- Duration: Warrants are exercisable from the date of issue until May 3, 2029.
Material Changes
The material change reported is the issuance of the aforementioned warrants, which was necessitated by revisions to the Company's loan agreement with Silicon Valley Bank and Kreos Capital V (UK) Limited. These revisions were previously announced in the Company's FY18 results statement issued on April 29, 2019.
Outlook, Risks, and Contingencies
Clinical Pipeline Status:
- BPS-804 (Osteogenesis Imperfecta): Phase 2b enrollment of 112 adults completed; initial data expected Q2 2019. Pediatric Phase 3 design approved by EMA.
- MPH-966 (Alpha-1 Antitrypsin Deficiency): First patient dosed in Phase 2 US study; data expected end of 2019.
- BCT-197 (COPD): Pivotal Phase 3 study outline announced following successful FDA Type B meeting.
- BGS-649 (Hypogonadotropic Hypogonadism): Positive Phase 2b data and safety extension results previously announced.
- Navicixizumab: Phase 1b trial in platinum-resistant ovarian cancer completed enrollment.
- Etigilimab: Currently in Phase 1b combination study with nivolumab.
Contingency: Celgene holds an option to obtain an exclusive license for Etigilimab. If exercised, Mereo (via OncoMed) is eligible to receive a $35 million opt-in payment.
Investor Verification Checklist
- Verify the specific terms of the revised loan agreement with Silicon Valley Bank and Kreos Capital referenced in the April 29, 2019 FY18 results.
- Confirm the current share price relative to the 295 pence warrant exercise price to assess immediate dilution risk.
- Monitor the Q2 2019 data release for BPS-804 and the end-of-2019 data release for MPH-966.
- Track Celgene's decision timeline regarding the exclusive license option for Etigilimab and the potential $35 million payment.